Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling

Medical Decision Making

Volumn 37, Issue 4, 2017, Pages 427-439

  Williams, Claire ^a   Lewsey, James D ^a   Mackay, Daniel F ^a   Briggs, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cost effectiveness analysis; Markov models; oncology; survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

CHRONIC LYMPHATIC LEUKEMIA; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; HUMAN; MARKOV CHAIN; MORTALITY; PROBABILITY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; STATISTICAL ANALYSIS; SURVIVAL ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MARKOV CHAINS; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 85019071886     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X16670617     Document Type: Article

References (32)

1. Glasziou PP, Simes RJ, Gelber RD., Quality Adjusted Survival Analysis. Stat Med. 1990; 9: 1259-76.
2. Gelber RD, Goldhirsch A, Cavalli F., Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer. Ann Intern Med. 1991; 114: 621-8.
3. Gelber RD, Cole BF, Gelber S, Goldhirsch A., Comparing Treatments Using Quality-Adjusted Survival: The Q-Twist Method. Am Statistician. 1995; 49: 161-9.
4. Beck JR, Pauker SG., The Markov process in medical prognosis. Med Decis Making. 1983; 3: 419-58.
5. Sonnenberg FA, Beck JR., Markov Models in Medical Decision Making: A Practical Guide. Med Decis Making. 1993; 13: 322-38.
6. Briggs A, Sculpher M., An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics. 1998; 13: 397-409.
7. Sun X, Faunce T., Decision-analytical modelling in health-care economic evaluations. Eur J Health Econ. 2008; 9: 313-23.
8. Hawkins N, Sculpher M, Epstein D,. Cost-Effectiveness of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response. Med Decis Making. 2005; 25: 511-9.
9. Bongers ML, de Ruysscher D, Oberije C, Lambin P, Uyl-de Groot CA, Coupe VMH,. Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity. Med Decis Making. 2016; 36: 86-100.
10. Williams C, Lewsey JD, Briggs AH, Mackay D., Cost-Effectiveness Analysis in R Using a Multi-State Modelling Survival Analysis Framework: A Tutorial. Med Decis Making. 2016 10 [Epub ahead of print]. DOI: 10.1177/0272989X16651869.
11. de Wreede LC, Fiocco M, Putter H., mstate: An R Package for the Analysis of Competing Risks and Multi-State Models. J Statist Software 2011; 38: 1-30. http://www.jstatsoft.org/v38/i07/.
12. R Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2015. http://www.R-project.org/. Last accessed: 31/08/2015.
13. Latimer NR., Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013; 33: 743-54.
14. Bagust A, Beale S., Survival analysis and extrapolation modelling of time-to-event clinical trial data for economic evaluation-an alternative approach. Med Decis Making. 2013; 34 343-51.
15. Grieve R, Hawkins N, Pennington M., Extrapolation of survival data in cost-effectiveness analyses: improving the current state of play. Med Decis Making. 2013; 33; 740-2.
16. Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S., Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006; 42: 2867-75.
17. Davies A, Briggs A, Schneider J., The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Res Med. 2012; 3: e25-e36.
18. Connock M, Hyde C, Moore D., Cautions regarding the fitting and interpretation of survival curves. Pharmacoeconomics. 2011; 29: 827-37.
19. National Institute for Health and Clinical Excellence. Rituximab for the first line treatment of chronic lymphocytic leukaemia. http://guidance.nice.org.uk/TA174 Last accessed: 31/08/2015.
20. Roche Products Limited. Rituximab for the 1st line treatment of Chronic Lymphocytic Leukaemia. National Institute for Health and Clinical Excellence 2008. http://www.nice.org.uk/guidance/ta174/resources/roche-submission2 Last. accessed: 31/08/2015.
21. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-74.
22. Office for National Statistics. Interim life tables (based on 2004-2006 UK population data). http://www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/interim-life-tables/index.html
23. Putter H, Fiocco M, Geskus RB., Tutorial in biostatistics: Competing risks and multi-state models. Stat Med. 2007; 26: 2389-2430.
24. Kuk D, Varadhan R., Model selection in competing risks regression. Stat Med. 2013; 32: 3077-3088.
25. Broström G., eha: Event History Analysis. R package version 2.2-6. 2013. http://CRAN.R-project.org/package=eha. Last accessed: 31/08/2015.
26. Jackson C,. flexsurv: Flexible parametric survival models. R package version 0.2. http://CRAN.R-project.org/package=flexsurv. Last accessed: 31/08/2015.
27. de Wreede LC, Fiocco M, Putter H., The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed. 2010; 99: 261-274.
28. Tuszynski J., caTools: Tools: moving window statistics, GIF, Base64, ROC AUC, etc. R package version 1.14. 2012. http://CRAN.R-project.org/package=caTools. Last accessed: 31/08/2015.
29. Davis S, Stevenson M, Tappenden P, Wailoo AJ., NICE DSU Technical Support Document 15: Cost-effectiveness modelling using patient-level simulation. 2014. http://www.nicedsu.org.uk. Last accessed: 10/02/2016.
30. van Houwelingen JC, le Cessie S., Predictive values of statistical models. Stat Med 1990; 8: 1303-25.
31. Greenland S,. Bayesian perspectives for epidemiological research II. Regression analysis. Int J Epidem 36: 1-8.
32. Jackson CH, (2011). Multi-State Models for Panel Data: The msm Package for R. J Statist Software 2011; 38: 1-29.